Hsieh, Chang-YuChang-YuHsiehTSEN-FANG TSAI2022-09-202022-09-202022-060961-2033https://scholars.lib.ntu.edu.tw/handle/123456789/621246The coexistence of psoriasis and cutaneous lupus erythematosus (LE) is uncommon. Treatment for concomitant psoriasis and LE is challenging because some valid treatments for LE such as hydroxychloroquine and systemic corticosteroid are known to aggravate psoriasis. Th17 pathway is shared by these two disease entities. Thus, biologics targeting Th17 pathway, including ustekinumab and secukinumab, have been successfully used in the treatment of patients with concomitant psoriasis and LE.enTh17; discoid lupus erythematosus; psoriasis; psoriatic arthritis; secukinumab[SDGs]SDG3review10.1177/09612033221095692354385952-s2.0-85128482819WOS:000784086600001https://scholars.lib.ntu.edu.tw/handle/123456789/610961